Kasabach-Merritt syndrome: pathogenesis and management.
Hall
G W
GW
Paediatric Haematology/Oncology Unit, John Radcliffe Hospital, Headley Way, Headington, Oxford OX3 DU9, UK. georgina.hall@cellsci.ox.ac.uk
D000925:Anticoagulants / Q000627:therapeutic use; D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004621:Embolization, Therapeutic; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D018324:Hemangioma, Capillary / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D016898:Interferon-alpha / Q000627:therapeutic use; D053685:Laser Therapy; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011696:Purpura, Thrombocytopenic / Q000175:diagnosis / Q000628:therapy*; D013577:Syndrome
D000925:Anticoagulants; D000933:Antifibrinolytic Agents; D005938:Glucocorticoids; D016898:Interferon-alpha; D010975:Platelet Aggregation Inhibitors